Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities

by Sanjiv, Kumar, Hagenkort, Anna, Calderón-Montaño, José Manuel, Koolmeister, Tobias, Reaper, Philip M., Mortusewicz, Oliver, Jacques, Sylvain A., Kuiper, Raoul V., Schultz, Niklas, Scobie, Martin, Charlton, Peter A., Pollard, John R., Berglund, Ulrika Warpman, Altun, Mikael, Helleday, Thomas
Published 2015

ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A

by Williamson, Chris T., Miller, Rowan, Pemberton, Helen N., Jones, Samuel E., Campbell, James, Konde, Asha, Badham, Nicholas, Rafiq, Rumana, Brough, Rachel, Gulati, Aditi, Ryan, Colm J., Francis, Jeff, Vermulen, Peter B., Reynolds, Andrew R., Reaper, Philip M., Pollard, John R., Ashworth, Alan, Lord, Christopher J.
Published 2016

Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970

by Hall, Amy B., Newsome, Dave, Wang, Yuxin, Boucher, Diane M., Eustace, Brenda, Gu, Yong, Hare, Brian, Johnson, Mac A., Milton, Sean, Murphy, Cheryl E., Takemoto, Darin, Tolman, Crystal, Wood, Mark, Charlton, Peter, Charrier, Jean-Damien, Furey, Brinley, Golec, Julian, Reaper, Philip M., Pollard, John R.
Published 2014